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Abstract
Background: Abdominal pain of unknown origin affects up to 20% of school-aged children. Evaluation of children
is symptom-based without clear guidelines to investigate molecular mechanisms of abdominal pain. Aberrant
molecular mechanisms may increase intestinal permeability leading to interactions between the immune and
nervous systems, subclinical inflammation, and visceral pain. This study evaluated the association between
interleukin-6 (IL-6), mast cell infiltrates, and serotonin (5-HT) levels in gastrointestinal (GI) biopsies, with perceived
abdominal pain in a pediatric cohort.
Methods: Clinical data and biopsy samples from pediatric patients (n = 48) with chronic abdominal pain, with and
without inflammation were included. Formalin-fixed paraffin-embedded GI biopsies were sectioned and
immunohistochemistry performed for IL-6 and 5-HT; mast cells were identified with toluidine blue stain.
Histological findings were compared to self-reported abdominal pain between groups.
Results: There was significantly greater IL-6 immunoreactivity in biopsies with confirmed histologic inflammation
(p = 0.004). There was a greater number of mast cells per HPF in non-inflammatory biopsies (3.5 ± 2.9) compared
to the inflammatory biopsies (2.6 ± 1.8) p = 0.049. The non-inflammatory biopsy group was significantly less likely
to respond to standard treatment as evidenced by higher pain reports (p = .018). Mast cells (p = .022) and 5-HT
(p = .02) were significantly related to abdominal pain scores.
Conclusions: A potential association between self-reported abdominal pain, number of mast cells, and 5-HT levels,
which may contribute to perceived GI pain in pediatric patients may exist.
Background
Unspecified chronic abdominal pain in children that has
no identified biologic marker or known organic cause
and has occurred for greater than two months is defined
by Rome III criteria as chronic abdominal pain [1]. These
criteria assume that no metabolic or structural causes
can be related to the continued symptoms of chronic
abdominal pain for an eight week period over the pre-
vious year. Current Rome III criteria divide pediatric
abdominal pain diagnosis into several subsets which
include functional abdominal pain syndrome and irritable
bowel syndrome (IBS) [2]. Approximately 15-20% of
children [3] and adults living in the United States suffer
from chronic abdominal pain [4,5]. Children with chronic
abdominal pain experience lessened quality of life in
comparison to their healthy peers which leads to numer-
ous absences from school for medical care [6,7]. Chronic
abdominal pain in pediatric patients is a significant bur-
den on the health system which warrants further investi-
gation on the pathogenesis of disease to identify novel
targets for intervention.
Recognition of the role of inflammation and its interac-
tion with the neuro-immune system of the gastrointest-
inal tract is an emerging area of interest in patients with
chronic abdominal pain [8]. The mechanisms of chronic
abdominal pain of unknown origin may be related to
interactions between the immune and nervous system in
the gut thereby leading to visceral hypersensitivity of the
intestinal mucosa [8]. Mast cells have been shown to
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tryptase, histamine, and possibly serotonin (5-hydroxy-
tryptamine, 5-HT) in humans [9]. There is evidence of
closer proximity of mast cells to nerve fibers in the colon
of IBS patients leading to augmented visceral sensitivity
[10]. A possible relationship between the number of
mucosal mast cells and rectal sensitivity has also been
demonstrated in humans [11]. There is evidence of a sig-
nificant increase in mast cell numbers in patients with
IBS [12]. Along with increased mast cell counts there is
s u p p o r tt h a tm a s tc e l ln u m b e rs directly correlate with
abdominal pain in IBS patients [13]. Recently, a study
conducted by Mahjoub, et al. found increased mast cell
density in pediatric patients with recurrent abdominal
pain [14]. They propose that mast cell density measure-
ments be incorporated with routine GI biopsies due to a
significant correlation between increase GI complaints
and mast cell count. Inflammation and increased perme-
ability of GI tract mucosa may also induce pain in pedia-
tric patients with functional abdominal pain [15].
Chronic abdominal pain of unknown origin may be
due to low grade inflammatory changes in the GI tract
[16,17]. Low level inflammation may result in increased
permeability across the mucosal barrier; which in turn
permits the entrance of antigens into the intestinal wall
[16]. Other potential mechanisms include altered func-
tion at the level of neurotransmitter receptors of 5-HT,
increased visceral hypersensitivity, and impaired colonic
mucosal permeability [18]. Alleviation of symptoms with
medication that target 5-HT receptors suggest that
5-HT is involved in gut motility regulation [19].
Increased permeability and its role in pediatric
abdominal pain has recently been the focus of work by
Shulman (2008). They explored the relationship of sub-
clinical inflammation and its relationship to chronic
pain of the GI tract. In a well-designed prospective con-
trolled study investigating the difference in GI perme-
ability and fecal calprotectin (marker for intestinal
inflammation) concentration in children with abdominal
pain versus control [15]. Proximal GI permeability, colo-
nic permeability, and fecal calprotectin were found to be
significantly greater in the abdominal pain group com-
pared to the control group. Fecal calprotectin concen-
trations correlated with pain interference with activities.
However, there was no correlation between GI perme-
ability and pain-related symptoms. This study high-
lighted that more research is needed to examine the
interactions at the molecular level between mast cells
and 5-HT.
These converging lines of evidence suggest that mast
cells and 5-HT contribute to increased colonic perme-
ability and thereby lead to chronic abdominal pain. We
assessed this hypothesis at the molecular level by explor-
ing the relationship between mast cell and 5-HT levels
and perceived abdominal pain in a pediatric cohort with
and without the diagnosis of an inflammatory GI
disorder.
Methods
Patients
This retrospective study sample included pediatric
patients who had undergone an initial outpatient GI and
endoscopic evaluation with biopsies as part of routine
evaluation for persistent abdominal pain and other asso-
ciated symptoms (Table 1). After diagnostic evaluation,
patients were classified as having abdominal pain that
was related to gross inflammation such as Crohn’sd i s -
ease or ulcerative colitis and whose pain subsequently
resolved on anti-inflammatory therapies versus those
with no evidence of both gross and histologic inflamma-
tion who continued to have abdominal pain. These
patients were considered to have functional abdominal
pain consistent with Rome III criteria. Formalin-fixed
paraffin-embedded biopsies (n = 48) from the esophagus
(4), antrum (1), stomach/gastric body (7), duodenum
(3), and colon/cecum (33) were available for pathologic
evaluation. A selection of samples from the prior 3 years
was purposely selected by a blinded pathologist across
phenotype, gender and age. The biopsies and data col-
lected were de-identified and received through a mate-
rial transfer agreement approved by the Institutional
Review Board (IRB) of Goryeb Children’sH o s p i t a la t
Atlantic Health, Morristown, New Jersey with the
National Institutes of Health (NIH).
Clinical data collection
All abdominal pain reports (categorized as no pain, mild,
moderate, or severe) were recorded before and after 6
months of endoscopic examination and medical treat-
ment as a part of routine clinical care. All patients
reported abdominal pain for more than 6 months prior
to endoscopy. Pre-existing data were extracted and re-
coded into a secure database without personal identifiers.
Clinical data included sex, race, age, body mass index
(BMI), and lactase deficiency. Data on race were collected
by electronic medical record review and categorized as
Caucasian, Asian, African American, Hispanic, and
mixed race. BMI was calculated from the initial outpati-
ent visit information with the formula age (years) by
weight (kilograms)/height (meters) squared. Medical
record data of confirmed lactase deficiency was collected
and categorized as positive or negative based on a duode-
nal biopsy disaccharidase assay (Women’s and Children’s
Hospital of Buffalo, Buffalo, NY).
Pathological examination
Biopsies were stained with hematoxylin and eosin, tolui-
dine blue and immunohistochemical markers at the
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tional Corporation (Frederick, MD). Microscopic histolo-
gic review of stains was performed by either a pathologist
or trained technicians who were blinded to clinical infor-
mation. Biopsies were categorized as either inflamed (with
evidence of chronic mucosal changes, villous/mucosal
atrophy, ulceration, cryptitis, crypt abscesses, or crypt
destruction) or not inflamed.
Mast cells identification was performed after the biop-
sies were sectioned (5-6 microns), de-paraffinized and
rinsed with 60% ethanol. Slides were then stained in
toluidine blue for 2 minutes, rinsed, and dehydrated in
acetone (2 times for 2 minutes). Slides were cleared in
xylene and mounted. Mast cell number was recorded as
the number of cells per 40× high power field (HPF) then
averaged 10 fields containing the maximum number of
mast cells.
For 5-HT immunohistochemistry, colonic GI tract
biopsies were sectioned (7 microns), de-paraffinized,
and incubated with 2% normal horse serum (Vector
Laboratories Inc. Burlingame, CA) for 20 minutes fol-
lowed by incubation with anti-5-HT antibody diluted
1:40 (Vision Biosystems, Newcastle, UK) for 30 minutes
at room temperature. Slides were rinsed and biotiny-
lated horse anti-mouse IgG antibody (Vector Labora-
tories Inc., Burlingame, CA) was applied for 30 minute
incubation. Immunoreactivity of 5-HT was identified by
positive stained entrochromaffin (EC) cells. The slides
were scored as: minimal (1-2 EC), mild (3-5 EC), mod-
erate (6-10 EC), or marked (more than 16 EC) by a
pathologist.
For IL-6 immunohistochemistry, biopsies were sec-
tioned (7 microns), de-paraffinized and blocked with 2%
normal goat serum (Vector Laboratories Inc. Burlin-
game, CA) for 20 minutes followed by incubation with
anti-IL-6 antibody diluted 1:400 (Vision Biosystems,
Newcastle, UK) at room temperature for 30 minutes.
Slides were then incubated for 30 minutes with biotiny-
lated goat anit-rabbit IgG (Vector Laboratories Inc.,
Burlingame, CA). The level of IL-6 immunoreactivity
was scored as: minimal, mild, moderate, or marked by a
pathologist.
Statistical methods
Data were collected, coded and doubly entered into
SPSS version 15.0. Statistical analysis included: means,
frequencies, standard deviation, independent t test and
Chi square analysis.
Ethical considerations
This study was approved by the NIH Office of Human
Subject Research (protocol #3906) and the Institutional
Review Board of Goryeb Children’s Hospital- Atlantic
Health (IRB #R07-09-009).
Results
The overall sample included pediatric patients (n =4 8 ) ,
54% female, with a mean age of 11.9 ± 2.9 yrs (range
5-17 yrs). After histological review, 22 pediatric GI biop-
sies were categorized as inflammatory and 26 pediatric
GI biopsies as non-inflammatory which coincided with
the original clinical diagnosis of disease (inflammatory
Table 1 Demographic and clinical indicators of sample
Variable Overall (n = 48) Group
All subjects were pain positive
Statistic
Non-Inflammatory
(n = 26)
Inflammatory
(n = 22)
n (%) n (%) n (%) p value
(c
2 /t-test)
Sex
Male 22 (45.8) 11 11 0.59
Female 26 (54.2) 15 11
Race
Caucasian 43 (89.6) 23 20 0.58
Asian 2 (4.2) 1 1
African American 1 (2.1) 1 0
Mixed 1 (2.1) 0 1
Hispanic 1 (2.1) 1 0
Age (M ± SD)
Range (yrs)
11.9 ± 2.9
(5-17)
11.9 ± 2.4
(8-16)
12 ± 2.9
(5-17
0.21
BMI (M ± SD)
Range
18.9 ± 4.3
(13-38.8)
19.5 ± 5.2
(13.8-38.8)
18.2 ± 4.3
(13-24.5)
0.431
Lactase Deficiency 24 (48) 16 8 0.387
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pain). There was no significant difference between the
phenotype (non-inflammatory and inflammatory GI
mucosa) with regard to sex, race, age, BMI or lactase
deficiency (Table 1).
Although there was no significant difference between
the patients abdominal pain reports at baseline (c
2 (2) =
0.58; p = 0.75) (Figure 1A), the response to standard
care was significantly related to the histology of the
patient’s biopsy as evidenced by patients with non-
inflamed biopsies reporting significantly higher pain
reports than patients with inflamed biopsies following
endoscopy/medical treatment (c
2 (2) = 11.67; p = 0.003)
(Figure 1B). The difference in the abdominal pain
reports (pre and post endoscopy/medical treatment) dif-
fered significantly between the two phenotypic groups
(c
2 (3) = 10.12; p = 0.018) (Figure 1C).
At baseline self-reported pain scores of patients with
non-inflamed biopsies were 35% mild, 45% moderate,
and 20% severe, compared to patients with inflamed
biopsies 23.5% mild, 53% moderate, and 23.5% severe
(Figure 1A). Post-treatment self-reported pain scores of
patients with non-inflamed biopsies were 47% no pain,
32% mild pain, 21% moderate pain; patients with
inflamed biopsies 95% reported no pain, 5% reported
mild pain (Figure 1B). The difference between pre and
post treatment self-reported pain scores for patients with
non-inflamed biopsies were 12.5% reported no change in
pain, 62.5% reported a mild change in pain, and 25%
reported moderate change in pain. The difference in pre
and post treatment self-reported pain scores of patients
with inflamed biopsies were 23.5% mild change in pain,
58.8% reported moderate change in pain, 17.6% reported
in a complete change in pain (Figure 1C).
Evaluation of toluidine blue stained sections showed
that there was a greater number of mast cells per HPF
in non-inflammatory biopsies (3.5 ± 2.9) compared to
the inflammatory biopsies (2.6 ± 1.8) p =0 . 0 4 9( F i g u r e
2). The number of mast cells (p = 0.022) and immunor-
eactivity of 5-HT (p = 0.02) per HPF were significantly
related to self-reported abdominal pain scores. Patients
with non-inflamed biopsies that had increased levels of
mast cells (Figure 3A and 3B) and 5-HT reported higher
post-treatment abdominal pain scores compared to
patients with inflamed biopsies (Figure 1B). Patients
with non-inflamed biopsies that failed to respond to
treatment (i.e., little change from baseline to post-
Figure 1 Self-reported abdominal pain scores. Self-reported
abdominal pain scores were dependent on the phenotype of non-
inflammatory or inflammatory. A. At baseline there is no significant
difference of self-reported abdominal pain between groups. B.A t
follow-up patients with inflamed biopsies reported lower pain
scores. C. Patients with non-inflamed biopsies had less change at
baseline compared to follow-up self reported pain scores.
Figure 2 Mast cells per HPF. Increased number of mast cells in
non-inflammatory biopsies compared to inflammatory biopsies.
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HT levels (mast cells r =- 0 . 4 2a n d5 - H Tr = -0.52).
Patients with inflamed biopsies that had increased levels
of mast cells and 5-HT reported higher change in pain
scores (r = 0.55). There was no difference in the amount
of staining for 5-HT between inflamed and non-
inflamed biopsies (c
2 (3) = 4.08; p =0 . 2 5 )( F i g u r e3 C
and 3D). The inflammatory biopsies had increased levels
of IL-6 immunoreactivity compared to the biopsies
without inflammation (c
2 (2) = 10.9; p = 0.004) (Figure
3E and 3F).
Discussion
In this study, we illustrate for the first time in the pedia-
tric population with chronic abdominal pain of unknown
origin that increased self-reported abdominal pain is cor-
related with higher levels of mast cells and 5-HT. All
patients, non-inflammatory and inflammatory, presented
with abdominal pain prior to endoscopic evaluation.
Patients with inflammation responded better to standard
care as evidenced by lower self-reported abdominal pain
scores post endoscopic evaluation. Patients with
decreased pain after standard treatment had lower mast
cell and 5-HT levels. The non-inflammatory cohort who
were unresponsive to standard medical care presented
with higher pain, had increased mast cells, and 5-HT
levels compared to the inflammatory cohort. This early
work may begin to explain some of the elusive etiology
related to chronic abdominal pain of unknown origin in
children.
This research tested the hypothesis that chronic
abdominal pain of unknown origin has an inflammatory
basis due to visceral activation by mast cells in the gut
(Figure 4). Mast cells not only degranulate and release
pro-inflammatory substances but also may be in closer
proximity to the cholinergic nerves thereby altering GI
motility and hypersensitivity (i.e., increased abdominal
pain) [10]. Mast cells may release other mediators besides
histamine and typtase that affect visceral hypersensitivity.
Our data suggests that 5-HT is an alternative mast cell
mediator which could interact with peripheral nerves
leading to increased sensitivity in the gut and chronic
abdominal pain. Our findings of increased mast cell and
5-HT immunoreactivity propose that these two compo-
nents of the immune system are related and contribute
to chronic abdominal pain of unknown origin in children.
Figure 3 Immunohistochemistry of mast cells, 5-HT, and IL-6
(magnification 60×). A-F. FFPE GI mucosa block sectioned and
immunostained for mast cells, 5-HT, and IL-6. A-B. Increased mast
cell counts per HPF in non-inflammatory biopsies compared to
inflammatory biopsies. C-D. No significant difference between
phenotypes in 5-HT immunoreactivity. E-F. Increased IL-6
immunoreactivity of inflammatory biopsies compared to non-
inflammatory biopsies.
Figure 4 Visceral activation of mast cells. Visual depiction of 5-
HT acting as a potential mediator between mast cells and
cholinergic nerves yielding visceral hypersensitivity.
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information which may be related to the mechanism
behind chronic abdominal pain of unknown origin. For
example, in post infectious IBS there may be a transloca-
tion of microbiota due to increased mucosa permeability
allowing for the interaction between inflammatory med-
iators and the enteric nervous system thereby stimulating
smooth muscle motility [20]. Patients with chronic
abdominal pain may be affected by a similar mechanism
at the molecular level of the GI mucosa. Increased per-
meability across the mucosal barrier may occur, in turn
leading to hypersensitivity and augmented pain.
Limitations
There are some limitations to this study including the
retrospective nature of data collection using medical
record review. Additionally, the limited sample size
makes the findings not necessarily generalizable to the
greater population of patients with chronic abdominal
pain of unknown origin. Furthermore, because of the
retrospective nature only associations are presented here
and care should be taken in the interpretation of these
findings as they do not imply direct causality. A future
study could include both direct objective and subjective
measures of abdominal pain as well as real-time mea-
sures of 5-HT, IL-6, and mast cell activation.
Conclusions
Recent advances on the role of 5-HT in the enteric ner-
vous systems and its relationship to intestinal visceral
hyperalgesia have contributed significantly to the under-
standing of abdominal pain and IBS in adults. This
increased knowledge has helped shift the paradigm that
these disorders are exclusively behavioral in nature and
that pathophysiologic disturbances at the cellular level
exist. To date, the consideration of inflammation and
intestinal pain has been traditionally reserved for condi-
t i o n ss u c ha sC r o h n ’s disease and ulcerative colitis. The
preliminary findings presented in this manuscript indi-
cate that similar relationships may exist in the pediatric
population with chronic abdominal pain of unknown
origin. Future research is needed in order to uncover
the associated causes of abdominal pain without inflam-
matory pathology in pediatric patients. Novel medical
treatments can arise by unveiling the role of mast cells
and 5-HT in the pathophysiology of chronic abdominal
pain of unknown origin in children.
Abbreviations
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